ストックスクリーナーアプリを入手
11.44
1.87%
0.21
アフターアワーズ：
11.44
前日終値:
$11.23
開ける：
$11.21
24時間の取引高:
652.13K
Relative Volume:
0.27
時価総額：
$811.10M
収益：
-
当期純損益:
$-117.81M
株価収益率:
-6.0851
EPS:
-1.88
ネットキャッシュフロー:
$74.30M
1週間 パフォーマンス:
+6.52%
1か月 パフォーマンス:
-10.76%
6か月 パフォーマンス:
+173.68%
1年 パフォーマンス:
+33.96%
1日の値動き範囲:
$11.05
$11.54
1週間の範囲:
$10.89
$11.54
52週間の値動き範囲:
$2.95
$17.65
Omeros Corporation Stock (OMER) Company Profile
名前
Omeros Corporation
セクター
電話
206-676-5000
住所
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
11.44 | 796.21M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-23 | 開始されました | D. Boral Capital | Buy |
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
| 2022-12-08 | ダウングレード | UBS | Buy → Neutral |
| 2022-11-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-06-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-10-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2021-10-01 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-09-27 | 開始されました | JP Morgan | Neutral |
| 2021-02-01 | 開始されました | UBS | Buy |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-08-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-14 | 繰り返されました | Maxim Group | Buy |
| 2019-05-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-12 | 開始されました | Seaport Global Securities | Buy |
| 2018-03-23 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-03-05 | ダウングレード | Needham | Buy → Hold |
| 2017-11-08 | 開始されました | H.C. Wainwright | Buy |
| 2017-05-11 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | 繰り返されました | Maxim Group | Buy |
| 2017-03-17 | 繰り返されました | Needham | Buy |
| 2016-11-16 | 繰り返されました | Wedbush | Outperform |
| 2016-11-10 | 繰り返されました | Needham | Buy |
| 2016-08-10 | 繰り返されました | Maxim Group | Buy |
| 2016-06-03 | 開始されました | Cantor Fitzgerald | Buy |
| 2016-03-02 | 繰り返されました | Needham | Buy |
| 2016-02-29 | 繰り返されました | Wedbush | Outperform |
| 2015-11-11 | 繰り返されました | Needham | Buy |
| 2015-08-18 | 繰り返されました | WBB Securities | Strong Buy |
| 2015-08-10 | 開始されました | ROTH Capital | Buy |
すべてを表示
Omeros Corporation (OMER) 最新ニュース
What risks investors should watch in Omeros Corporation stockWeekly Investment Report & Long-Term Safe Investment Plans - mfd.ru
Omeros Achieves Commercial Milestone with First Approved Drug Launch - AD HOC NEWS
Macro Review: What is the long term forecast for Omeros Corporation stockStock Surge & Community Shared Stock Ideas - baoquankhu1.vn
Omeros Corporation's (NASDAQ:OMER) market cap dropped US$60m last week; individual investors who hold 50% were hit as were institutions - Yahoo Finance
Omeros wins FDA nod for transplant therapy - MSN
Omeros Corporation (NASDAQ:OMER) Sees Large Growth in Short Interest - MarketBeat
EV Market: Is Omeros Corporation gaining market shareTrade Entry Report & Daily Profit Focused Stock Screening - baoquankhu1.vn
Omeros higher after first commercial sales of transplant therapy - MSN
Is Omeros Corporation gaining market shareJuly 2025 Gainers & Safe Entry Momentum Stock Tips - mfd.ru
Omeros begins commercial distribution of TA-TMA treatment Yartemlea By Investing.com - Investing.com Australia
Big Money Moves: What is the implied volatility of Air Products and Chemicals IncWeekly Market Outlook & Real-Time Market Sentiment Reports - baoquankhu1.vn
Omeros Shares Rise After Starting Commercial Sales of Stem Cell Complication Drug Yartemlea - marketscreener.com
Omeros (OMER) Rises on First Shipments of Yartemlea - GuruFocus
Omeros wins first commercial sales of Yartemlea (OMER:NASDAQ) - Seeking Alpha
OMER: D. Boral Capital Maintains Buy Rating with $36 Price Targe - GuruFocus
Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital - MarketBeat
Omeros stock rises as first commercial YARTEMLEA shipments begin By Investing.com - Investing.com Canada
Omeros stock rises as first commercial YARTEMLEA shipments begin - Investing.com
Omeros Begins Commercial Sales of Stem Cell Complication Drug Yartemlea - marketscreener.com
Omeros (OMER) Begins Commercial Distribution of Yartemlea for TA-TMA - GuruFocus
Omeros announces first commercial sales of Yartemlea - TipRanks
Omeros begins commercial distribution of TA-TMA treatment Yartemlea - Investing.com
Omeros Announces First Commercial Sales of YARTEMLEA® - Yahoo Finance
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now? - AOL.com
Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Portfolio Update: Can Omeros Corporation maintain sales growthJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Growth Value: Should you buy the dip on Omeros CorporationQuarterly Growth Report & Fast Gain Stock Tips - baoquankhu1.vn
Omeros Shares Face Headwinds Amid Mixed Signals - AD HOC NEWS
Omeros stock garners high retail attention ahead of FDA verdict for life-saving drug - MSN
Omeros (NASDAQ:OMER) Shares Down 5.8% Following Insider Selling - MarketBeat
Omeros (NASDAQ:OMER) CAO Sells 30,000 Shares - MarketBeat
Omeros (OMER) Price Target Increased by 29.70% to 44.54 - Nasdaq
Omeros VP Borges sells $750k in shares By Investing.com - Investing.com Nigeria
Omeros VP Borges sells $750k in shares - Investing.com
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - msn.com
HC Wainwright Has Bearish Outlook for Omeros FY2026 Earnings - MarketBeat
Why did Omeros stock jump 5% in after-hours trading today? - MSN
Omeros (OMER) Price Target Increased by 12.22% to 34.34 - MSN
Omeros Corporation (OMER) 財務データ
収益
当期純利益
現金流量
EPS
Omeros Corporation (OMER) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Borges David J. | VP, Finance & CAO |
Jan 12 '26 |
Sale |
12.72 |
30,000 |
381,600 |
0 |
| Borges David J. | VP, Finance & CAO |
Jan 13 '26 |
Sale |
12.31 |
30,000 |
369,315 |
0 |
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):